Nuwellis (NUWE)
NASDAQ:NUWE
Want to see NUWE full AI Analyst Report?
NUWE Stock Chart & Stats
$1.76
-$0.08(-7.15%)
At close: 4:00 PM EST
$1.76
-$0.08(-7.15%)
Day’s Range― - ―
52-Week Range$0.90 - $40.07
Previous CloseN/A
Volume102.02K
Average Volume (3M)289.18K
Market Cap
$2.67M
Enterprise Value-$870.20K
Total Cash (Recent Filing)$2.08M
Total Debt (Recent Filing)$265.00K
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Aug 11, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-64.02
Shares Outstanding2,680,752
10 Day Avg. Volume82,161
30 Day Avg. Volume289,177
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.58
Price to Sales (P/S)1.45
P/FCF Ratio-1.10
Enterprise Value/Market Cap-0.33
Enterprise Value/Revenue-0.10
Enterprise Value/Gross Profit-0.15
Enterprise Value/Ebitda0.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.69
Revenue Forecast (FY)$9.01M
Bulls Say, Bears Say
Bulls Say
Commercial Execution And Supply StabilityShift to a direct-selling model in the United States and migration of manufacturing to a contract partner is intended to improve commercial execution, stabilize supply, and enhance product quality, which could increase sales efficiency.
Earnings And Revenue MomentumResults modestly exceeded analyst expectations as stronger console sales, higher utilization across the installed base, and improved circuit pricing supported revenue momentum.
Product Portfolio Expansion And Clinical CapabilityAcquisition of Rendiatech integrates real-time urine flow and kidney injury monitoring into the Aquadex platform, expanding offerings for hospital customers and strengthening the critical care value proposition.
Bears Say
Financing Needs And Dilution RiskLimited cash runway and the likely need for additional capital raise introduce a risk of shareholder dilution and create uncertainty about the path to sustainable profitability.
Integration And Commercialization UncertaintyUndefined integration timelines for acquired technologies and an unclear commercialization strategy create uncertainty about when acquisitions will meaningfully contribute to sales.
International Revenue SustainabilityA spike in international consumable sales was driven by exiting certain markets, making those sales non-recurring and weakening the sustainability of international revenue growth.
Nuwellis News
NUWE FAQ
What was Nuwellis’s price range in the past 12 months?
Nuwellis lowest stock price was $0.90 and its highest was $40.07 in the past 12 months.
What is Nuwellis’s market cap?
Nuwellis’s market cap is $2.67M.
When is Nuwellis’s upcoming earnings report date?
Nuwellis’s upcoming earnings report date is Aug 11, 2026 which is in 80 days.
How were Nuwellis’s earnings last quarter?
Nuwellis released its earnings results on May 12, 2026. The company reported -$2.09 earnings per share for the quarter, missing the consensus estimate of -$1 by -$1.09.
Is Nuwellis overvalued?
According to Wall Street analysts Nuwellis’s price is currently Overvalued.
Does Nuwellis pay dividends?
Nuwellis does not currently pay dividends.
What is Nuwellis’s EPS estimate?
Nuwellis’s EPS estimate is -0.68.
How many shares outstanding does Nuwellis have?
Nuwellis has 2,680,752 shares outstanding.
What happened to Nuwellis’s price movement after its last earnings report?
Nuwellis reported an EPS of -$2.09 in its last earnings report, missing expectations of -$1. Following the earnings report the stock price went down -0.962%.
Which hedge fund is a major shareholder of Nuwellis?
Currently, no hedge funds are holding shares in NUWE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuwellis
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
NUWE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple positive operational and strategic developments (notably 26% revenue growth, a 70.1% gross margin, pediatric adoption, the RendiaTech acquisition, a new patent, leadership and board strengthening, and a ~$5M capital infusion). However, notable challenges remain: a ~$4.3M net loss, operating expenses up ~46%, modest cash on hand (~$2.2M), and a multi-quarter timeline to commercialize RendiaTech's target product. On balance, the highlights indicate meaningful early execution progress and strategic positioning, but the company must deliver on its burn reduction and commercialization milestones to sustain momentum.View all NUWE earnings summariesNUWE Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Aethlon Medical
―
PAVmed
―
Catheter Precision
―
Bone Biologics
―
Heart Test Laboratories, Inc.
―
Ownership Overview
41.03% Insiders
0.50% Mutual Funds
8.81% Other Institutional Investors
49.65% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---